InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
Phase 3positivefadeucravacitinibPositive
AI Analysis
Summary
InnoCare's TYK2 inhibitor fadeucravacitinib (ICP-488) met its primary endpoint and multiple secondary endpoints in a Phase III psoriasis clinical study.
Clinical Trial Data
Phase
III
Primary Endpoint
Met
Outcome Details
Met primary endpoint and multiple secondary endpoints
Importance:8/10
Sentiment:
0.85
TYK2 inhibitorpsoriasisPhase 3clinical trialpositive data
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 27, 2026 10:50 AM